Want to see IN:EPIGRAL full AI Analyst Report?
EPIGRAL Stock Chart & Stats
₹1163.05
-₹5.70(-0.49%)
At close: 4:00 PM EDT
₹1163.05
-₹5.70(-0.49%)
Day’s Range― - ―
52-Week Range₹806.20 - ₹1,729.75
Previous CloseN/A
Volume649.06K
Average Volume (3M)2.45K
Market Cap
₹43.00B
Enterprise Value₹40.59B
Total Cash (Recent Filing)₹50.20M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)15.8
Beta1.39
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.5%
Share Statistics
EPS (TTM)62.82
Shares Outstanding43,141,340
10 Day Avg. Volume2,271
30 Day Avg. Volume2,448
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.40
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)66.9
Revenue Forecast (FY)₹27.01B
Bulls Say, Bears Say
Bulls Say
Healthy ProfitabilityLatest operating and net margins of about 16% and 13% show the company retains meaningful profitability in its specialty-chemical operations. This provides internal earnings capacity to support reinvestment and cushions the business against moderate demand or cost pressure over coming quarters.
Strengthened Balance SheetThe sharp reduction in leverage materially improves financial resilience and reduces balance-sheet pressure. With debt at roughly 0.26x equity and equity expanding, Epigral has greater flexibility to fund operations and manage weaker periods without relying heavily on additional borrowing.
Long-Term Revenue ExpansionStrong revenue growth over the longer term indicates that Epigral has expanded its business base within the textile and specialty-chemical markets. That accumulated scale can support customer relationships, operating leverage, and future growth if demand and product mix improve.
Bears Say
Weak Free Cash FlowThe move to negative free cash flow weakens earnings quality because reported profits are not currently converting into available cash. If this persists, it could constrain internally funded investment, increase reliance on working-capital management, and reduce financial flexibility.
Margin Compression And Flat RevenueFlat revenue alongside materially lower gross and operating margins signals pressure on pricing, product mix, or operating efficiency. Sustained compression would reduce earnings resilience and make it harder for the company to convert market presence into consistent profit growth.
Declining Earnings MomentumA decline of nearly 38% in EPS indicates that shareholder earnings have weakened substantially, even though the business remains profitable. Continued earnings deterioration could limit reinvestment capacity, weaken returns, and signal that recent profitability levels may not be fully sustainable.
Epigral Ltd News
EPIGRAL FAQ
What was Epigral Ltd’s price range in the past 12 months?
Epigral Ltd lowest stock price was ₹806.20 and its highest was ₹1729.75 in the past 12 months.
What is Epigral Ltd’s market cap?
Epigral Ltd’s market cap is ₹43.00B.
When is Epigral Ltd’s upcoming earnings report date?
Epigral Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 24 days.
How were Epigral Ltd’s earnings last quarter?
Epigral Ltd released its earnings results on Jul 27, 2026. The company reported ₹23.119 earnings per share for the quarter.
Is Epigral Ltd overvalued?
According to Wall Street analysts Epigral Ltd’s price is currently Overvalued.
Does Epigral Ltd pay dividends?
Epigral Ltd pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.5%. See more information on Epigral Ltd dividends here
What is Epigral Ltd’s EPS estimate?
Epigral Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epigral Ltd have?
Epigral Ltd has 43,141,340 shares outstanding.
What happened to Epigral Ltd’s price movement after its last earnings report?
Epigral Ltd reported an EPS of ₹23.119 in its last earnings report. Following the earnings report the stock price went down -0.284%.
Which hedge fund is a major shareholder of Epigral Ltd?
Currently, no hedge funds are holding shares in IN:EPIGRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Epigral Ltd
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash. Additionally, the company is involved in the trading of agrochemical products. Epigral caters to an extensive list of industries, including CPVC pipes and fittings, wind energy, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soaps and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. Incorporated in 2007 and based in Ahmedabad, India, the company was formerly known as Meghmani Finechem Limited until it adopted the name Epigral Limited in August 2023.
Technical Analysis
Deepak Nitrite Limited
―
Gujarat Alkalies & Chemicals Ltd.
―
Indo Amines Limited
―
Styrenix Performance Materials Ltd
―
Valiant Organics Limited
―